靶向左氧氟沙星脂质体的制备及其抗耐药菌作用的研究-东南大学学报医学版

靶向左氧氟沙星脂质体的制备及其抗耐药菌作用的研究

单位：1. 东南大学医学院, 江苏南京 210009;
2. 东南大学附属中大医院检验科, 江苏南京 210009

分类号：R918;R978.19

出版年·卷·期（页码）：2015·34·第一期（27-31）

摘要：

目的:制备具有靶向性抗耐药菌作用的左氧氟沙星脂质体,并考察其体外抗菌活性。方法:采用硫酸铵梯度法,用Ts修饰脂质体膜,制备具双重杀菌机制的靶向左氧氟沙星脂质体,考察其表征及包封率。比较游离左氧氟沙星、左氧氟沙星与Ts联合、非靶向及靶向左氧氟沙星脂质体对耐药菌株的最小抑菌浓度(MIC)及对肺炎克雷伯标准菌株的时间杀菌活性,并分析协同效应。结果:靶向左氧氟沙星脂质体包封率(75.26±1.35)%,粒径(152.5±3.2)nm,zeta电位+20.68±1.72,多分散性0.149 ±0.02,1个月内稳定性较好,其MIC均低于其他剂型,FIC≤0.5,显示协同效应;在同一时间内抑菌数量最多,时间杀菌效果显著。结论:相对游离剂型和非靶向脂质体,靶向左氧氟沙星脂质体对耐药菌具备更强的抗菌活性。

Objective: To prepare levofloxacin liposome with targeting antagonizing drug-resistance bacteria effect and observe its antimicrobial activity in vitro. Methods: Ammonium sulfate gradient method and modify the liposome membrane with Ts were used to produce targeting levofloxacin liposome with double antibacterial mechanisms. MIC (minimum inhibitory Concentration) and time-bactericidal activity to pneumonia klebsiella were compared among free levofloxacin, levofloxacin combined with Ts, non-targeting and targeting levofloxacin liposome and analysis synergistic effect. Results: The encapsulation efficiency of targeting levofloxacin liposome was(75.26±1.35)%, partical size was(152.5±3.2)nm, Zeta potential was+20.68±1.72, and polydispersity was 0.149±0.02. Liposome was stable for one month. The MIC was lower than other forms. FIC≤0.5 showed synergistic effect. During the same time, it inhibited most bacteria with outstanding time-bactericidal activity. Conclusion: Comparing with free and non-targeting liposome, targeting levofloxacin liposome has greater bactericidal activity to drug-resistance bacteria.

参考文献：

[1] 罗大勇,柯英,陈鸿.左氧氟沙星替代吡嗪酰胺治疗老年性肺结核的临床观察[J].现代医学,2012,40(4):439-441.
[2] 单爱莲,赵桂元,钱思源.左氧氟沙星不良反应的国内外文献个案调查与分析[J].中国临床药理学杂,2012,28(3):212-217.
[3] WU G Q, WU H B,LI L X,et al.Membrane aggregation and perturbation induced by antimicrobial peptide of S-thanatin[J].Biochem Biophys Res Commun,2010,395(1):31-35.
[4] WU G Q,WU H B,LI L X,et al.Structural analysis and the causes of non-toxicity of antimicrobial peptide S-thanatin[J].Peptides,2010,31(9):1669-1673.
[5] WU G Q,LI L X,WANG H L,et al.Interaction of antimicrobial peptide S-thanatin with lipopolysaccharide in vitro and in experimental mouse models of septic shock caused by multidrug-resistant clinical isolate of Escherichia coli[J].Int J Antimicrob Agents,2010,35(3):250-254.
[6] 张青,朱家壁,邱丽梅.盐酸左氧氟沙星脂质体的包封率和体外释放的研究[J].中国药科大学学报,2004,35(6):508-512.
[7] 杨杜明,徐永清,李福兵,等.脂质体作为抗生素载体的研究进展[J].中国修复重建外科杂志,2012,26(11):1387-1390.
[8] 曹宁宁,羡菲,刘金鹏.脂质体的制备方法及研究进展[J].天津理工学院学报,2003,19(1):30-35.
[9] HARAN G,COHEN R,BAR L K,et al.Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases[J].Biochim Biophys Acta,1993,1151(2):201-215.
[10] FURNERI P M,FRESTA M,PUGLISI G,et al.Ofloxacin-loaded liposomes:in vitro activity and drug accumulation in bacteria[J].Antimicrob Agents Chemother,2000,44(9):2458-2464.
[11] National Committee for Clinical Laboratory Standards.Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically:approved standard[S].6th ed.WAYNE P A,2003: NCCLS document M7-A6.
[12] 张永青,王睿,朱曼,等.加替沙星或环丙沙星联合头孢美唑对大肠埃希菌的抗菌效应分析[J].临床内科杂志,2006,23(3):193-195.
[13] DRULIS-KAWA Z,DOROTKIEWICZ-JACH A.Liposomes as delivery systems for antibiotics[J].Int J Pharm,2010,387(1-2):187-198.
[14] GREGORIADIS G.Engineering liposomes for drug delivery: progress and problems[J].Trends Biotechnol,1995,13(12):527-537.
[15] SHARMA A,SHARMA U S.Liposomes in drug delivery: progress and limitations[J].Int J Pharm,1997,154(2):123-140.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录